Hospitalization for adverse events under abiraterone or enzalutamide exposure in real‐world setting: A French population‐based study on prostate cancer patients

Aims Safety profiles of abiraterone and enzalutamide rely mainly on Phase III clinical trials. Our objective was to estimate the incidence rate ratio (IRR) for certain adverse events leading in real life to hospitalization (atrial fibrillation, acute heart failure, ischaemic heart disease, acute kid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of clinical pharmacology 2022-01, Vol.88 (1), p.336-346
Hauptverfasser:	Scailteux, Lucie‐Marie, Despas, Fabien, Balusson, Frédéric, Campillo‐Gimenez, Boris, Mathieu, Romain, Vincendeau, Sébastien, Happe, André, Nowak, Emmanuel, Kerbrat, Sandrine, Oger, Emmanuel
Format:	Artikel
Sprache:	eng
Schlagworte:	abiraterone acute kidney injury Acute Kidney Injury - chemically induced adverse events Androstenes - adverse effects Atrial Fibrillation - chemically induced Benzamides - adverse effects Bioengineering Brain Ischemia - chemically induced castration‐resistant prostate cancer enzalutamide Hospitalization Humans Life Sciences liver test monitoring Male Nitriles - adverse effects Phenylthiohydantoin - adverse effects Prostatic Neoplasms, Castration-Resistant - drug therapy safety Stroke - chemically induced Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!